Who benefits from high-dose therapy for multiple myeloma?

A high-throughput platform for biophysical antibody developability assessment to enable AI/ML model training.

mAbs·2025

Report of consensus panel 7 from the 11th international workshop on Waldenström macroglobulinemia on priorities for novel clinical trials.

Seminars in hematology·2023

Correction: Management of relapsed and refractory multiple myeloma: novel agents, antibodies, immunotherapies and beyond.

Leukemia·2019

Correction: Pomalidomide, bortezomib, and low-dose dexamethasone in lenalidomide-refractory and proteasome inhibitor-exposed myeloma.

Leukemia·2018

Management of relapsed and refractory multiple myeloma: novel agents, antibodies, immunotherapies and beyond.

Leukemia·2017

Protein arginine methyltransferase 5 has prognostic relevance and is a druggable target in multiple myeloma.

Leukemia·2017

Pathologic Complete Response (pCR) Rate and Predictors of Response to Taxane, Trastuzumab, and Pertuzumab in HER2‑Positive Breast Cancer: Secondary Analyses of EA1181/CompassHER2 pCR.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026

Therapy for Stage IV Non-Small Cell Lung Cancer With Driver Alterations: ASCO Living Guideline, Version 2026.3.3.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026

Immunotherapy and Targeted Therapy for Advanced Gastroesophageal Cancer: ASCO Living Guideline, Version 2026.1.2.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026

Laser Interstitial Thermal Therapy for Brain Tumors: A Prospective Multicenter Analysis of Patients From the LAANTERN Study.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026

Mosunetuzumab With Response-Adapted Polatuzumab Vedotin and Obinutuzumab in Untreated Indolent B-Cell Non-Hodgkin Lymphoma.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026

COMBI-I: Long-Term Overall Survival With Spartalizumab Plus Dabrafenib and Trametinib in BRAF V600-Mutant Advanced Melanoma.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026

Older Age, STAG2, and DNMT3A Mutations Predict Superior Posttransplant Survival in Newly Diagnosed Acute Myeloid Leukemia Treated With Venetoclax Plus Hypomethylating Agents.

American journal of hematology·2026

Research Progress in Pharmacological Targeted Therapy for Myasthenia Gravis.

Journal of inflammation research·2026

Internet-delivered unguided psychodynamic vs. cognitive behavior therapy for anxiety and depression symptoms: A large, full factorial randomized controlled trial on treatment length and peer support.

Internet interventions·2026

Adverse effects of vanzacaftor-tezacaftor-deutivacaftor in a cystic fibrosis population: A case series.

Respiratory medicine case reports·2026

Advances in gene transfer technologies: comparing viral and non-viral vectors for therapeutic applications.

3 Biotech·2026

Exploration of the therapeutic potential of the HRH3 histamine receptor in MECP2-related disorders.

Neuropharmacology·2026

Related Experiment Videos

Who benefits from high-dose therapy for multiple myeloma?

Related Concept Videos

A high-throughput platform for biophysical antibody developability assessment to enable AI/ML model training.

Report of consensus panel 7 from the 11th international workshop on Waldenström macroglobulinemia on priorities for novel clinical trials.

Correction: Management of relapsed and refractory multiple myeloma: novel agents, antibodies, immunotherapies and beyond.

Correction: Pomalidomide, bortezomib, and low-dose dexamethasone in lenalidomide-refractory and proteasome inhibitor-exposed myeloma.

Management of relapsed and refractory multiple myeloma: novel agents, antibodies, immunotherapies and beyond.

Protein arginine methyltransferase 5 has prognostic relevance and is a druggable target in multiple myeloma.

Pathologic Complete Response (pCR) Rate and Predictors of Response to Taxane, Trastuzumab, and Pertuzumab in HER2‑Positive Breast Cancer: Secondary Analyses of EA1181/CompassHER2 pCR.

Therapy for Stage IV Non-Small Cell Lung Cancer With Driver Alterations: ASCO Living Guideline, Version 2026.3.3.

Immunotherapy and Targeted Therapy for Advanced Gastroesophageal Cancer: ASCO Living Guideline, Version 2026.1.2.

Laser Interstitial Thermal Therapy for Brain Tumors: A Prospective Multicenter Analysis of Patients From the LAANTERN Study.

Mosunetuzumab With Response-Adapted Polatuzumab Vedotin and Obinutuzumab in Untreated Indolent B-Cell Non-Hodgkin Lymphoma.

COMBI-I: Long-Term Overall Survival With Spartalizumab Plus Dabrafenib and Trametinib in BRAF V600-Mutant Advanced Melanoma.

Older Age, STAG2, and DNMT3A Mutations Predict Superior Posttransplant Survival in Newly Diagnosed Acute Myeloid Leukemia Treated With Venetoclax Plus Hypomethylating Agents.

Research Progress in Pharmacological Targeted Therapy for Myasthenia Gravis.

Internet-delivered unguided psychodynamic vs. cognitive behavior therapy for anxiety and depression symptoms: A large, full factorial randomized controlled trial on treatment length and peer support.

Adverse effects of vanzacaftor-tezacaftor-deutivacaftor in a cystic fibrosis population: A case series.

Advances in gene transfer technologies: comparing viral and non-viral vectors for therapeutic applications.

Exploration of the therapeutic potential of the HRH3 histamine receptor in MECP2-related disorders.

Related Experiment Videos

Who benefits from high-dose therapy for multiple myeloma?

Related Concept Videos

Related Articles